Vascular risk factors and Alzheimer's disease

John T O'Brien1, Hugh S Markus

  • 1Department of Psychiatry, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK. john.obrien@medschl.cam.ac.uk.

BMC Medicine
|November 12, 2014
PubMed

Insights

Vascular factors significantly increase the risk of cognitive decline, including Alzheimer's disease (AD) and vascular dementia. Managing cardiovascular health may help slow AD progression, but more research is needed.

Area of Science:

  • Neuroscience and Neurology
  • Cardiovascular Science
  • Gerontology

Background:

  • Vascular factors are recognized risks for cognitive decline, dementia, Alzheimer's disease (AD), and vascular dementia.
  • These factors may accelerate Alzheimer's pathology (plaque and tangle formation) or impair its clearance.

Discussion:

  • Reviews in BMC Medicine explore the clinical, pathological, and therapeutic links between AD and cardiovascular diseases.
  • The precise relationship between vascular factors and AD requires further elucidation.
  • High-quality treatment studies are lacking to assess the impact of vascular risk modification on AD progression.

Key Insights:

  • Strong clinical and pathological evidence links vascular factors to AD.
  • Vascular risk factors appear to influence the development and progression of AD pathology.
  • Intervention studies are crucial to validate the role of vascular risk management in AD.

Outlook:

  • Further longitudinal studies are needed to understand the mechanisms linking vascular health and AD.
  • Therapeutic research should focus on whether treating vascular risk can prevent or delay AD onset.
  • Investigating the impact of vascular risk reduction on the clinical progression of AD is essential.

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
6
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
4
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
7
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
737